Filing Flows › Opus Genetics (IRD) › Q4 2024
Opus Genetics (IRD) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 31, 2025
Opus Genetics (IRD) reported revenue of $4.3M for the fourth quarter 2024 (Q4 2024), +154% from a year earlier and +11% from the quarter before. Operating margin was -884.0%, net loss $35.1M (816.7% of revenue).
Opus Genetics, Q4 2024: revenue $4.3M (+154% year over year), operating margin -884.0%, net loss $35.1M, operating cash flow −$7.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.3M | +11% | +154% |
| Operating profit | −$38.0M | — | — |
| Net earnings | −$35.1M | — | — |
| Operating cash flow | −$7.4M | — | — |
What changed
Revenue was $4.3M in Q4 2024, up 154% year over year and up 11% from the previous quarter.
Operating costs exceeded revenue by $38.0M, an operating margin of -884.0%. Total costs grew 495% against revenue growth of 154%. The fastest-growing cost line was General & admin (+123%). The quarter ended with a net loss of $35.1M, wider than the previous quarter's $7.5M loss.
Operating cash flow was −$7.4M. Non-cash charges added back $10K of depreciation and $795K of share-based compensation. Working capital and other items added $26.9M.
Questions
What was Opus Genetics' revenue in the fourth quarter 2024?
Opus Genetics (IRD) reported revenue of $4.3M for the fourth quarter 2024 (Q4 2024), +154% from a year earlier and +11% from the quarter before.
Was Opus Genetics profitable in the fourth quarter 2024?
Operating loss was $38.0M (-884.0% of revenue) and net loss $35.1M.
Source: Opus Genetics 10-K on SEC EDGAR.